Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $62.78 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Antero Resources (AR) PT Raised to $47 at Benchmark on Natural Gas Bull Case
• ARAMARK Holdings (ARMK) PT Raised to $71 at UBS on Beat and Raise Q3 Results
• Abercrombie & Fitch (ANF) PT Raised to $153 at UBS on Decent Q2, Stable Trend Across Brands